SCHEMBL21853751

SCHEMBL21853751

CS(=O)(=O)c1ccc([C@@H](O)[C@@H](N)C(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
NR1I2 O75469 1/20 0.51
PTGS1 P23219 1/20 0.51
ADRA1A P35348 1/20 0.51
BLM P54132 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
GRM4 Q14833 1/20 0.51
ACHE P22303 1/20 0.50
TSHR P16473 1/20 0.48
MEN1 O00255 1/20 0.47
CYP3A4 P08684 1/20 0.47
KMT2A Q03164 1/20 0.47
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
ENPP2 Q13822 1/20 0.42
SLC1A2 P43004 4/20 0.42
SLC1A3 P43003 3/20 0.42
SLC1A1 P43005 3/20 0.42
DPP4 P27487 1/20 0.40
DPP7 Q9UHL4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21853762 1.00 LMNA (0.51) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL32674587 1.00 LMNA (0.51) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL21791552 1.00 LMNA (0.51) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL2065376 1.00 LMNA (0.51) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL4247092 1.00 LMNA (0.51) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL9007595 1.00 LMNA (0.51) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL4594968 0.98 LMNA (0.50) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL18211545 0.86 LMNA (0.48) LMNANR1I2PTGS1ADRA1AGRM4
SCHEMBL4594965 0.85 LMNA (0.47) LMNANR1I2PTGS1ADRA1ABLM
SCHEMBL31345284 0.83 GRM4 (0.42) LMNANR1I2PTGS1ADRA1ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630795-B1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF ENZYMASTER NINGBO BIO ENG CO LTD (CN) 2023-07-26 EP disclosed
US-11274287-B2 Engineered aldolase polypeptides and uses thereof Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) 2022-03-15 US disclosed
US-20200123525-A1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) 2020-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274287-B2 Engineered aldolase polypeptides and uses thereof DERA, ALDOA, TKT LMNA 1584/4885NR1I2 3487/4885PTGS1 2842/4885
US-20200123525-A1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF DERA, ALDOA, TKT LMNA 1584/4885NR1I2 3487/4885PTGS1 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.